Medicine
Psychedelic Medicine Is Coming. The Law Isn’t Ready
A surprising resurgence of psychedelic research has produced its first FDA-approved treatment, with more likely on the way
Stories by Matt Lamkin
Matt Lamkin is an associate professor at the University of Tulsa College of Law and served as a fellow at Stanford Law School's Center for Law and the Biosciences. His work has been published in the New England Journal of Medicine, JAMA Psychiatry, Bioethics, the AMA Journal of Ethics, the Journal of Law, Medicine, and Ethics, and numerous legal journals.
